// App-Quantinova.ai

695 : Omalizumab is associated with a reduced need for surgery in patients with nasal polyposis

Researchers

Presenter

  • Gevaert P

Principal Investigators

  • Hellings PW

  • Han JK

  • Mullol J

  • Olsson P

  • Zhao R

  • Saenz R

  • Islam L

  • Omachi T

Medical Centers

  • Upper Airway Research Laboratory, Department of Otorhinolaryngology, Ghent University Hospital, Ghent, Belgium,

  • Clinical division of Otorhinolaryngology, Head & Neck Surgery, University Hospitals, Leuven, Belgium

  • Laboratory of Clinical Immunology, KU Leuven, Department of Microbiology and Immunology, Leuven, Belgium

  • Eastern Virginia Medical School, Norfolk, Virginia, United States

  • Rhinology Unit & Smell Clinic, ENT Department, Hospital Clinic, IDIBAPS, Universitat de Barcelona, CIBERES, Barcelona, Spain

  • Sacramento Ear, Nose and Throat Surgical and Medical Group, Inc., Sacramento, California, United States

  • Novartis Sverige AB, Kista, Stockholm, Sweden

  • Second Genome, Inc., South San Francisco, California, United States

  • Roche, Welwyn Garden City, Hertfordshire, United Kingdom

Locations

  • Belgium

  • United States

  • Spain

  • Sweden

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Asthma

Biomarkers

  • N/A

Drug/Treatment

  • Omalizumab

  • Immunol

Outcome

  • N/A

Study Design

  • Placebo Control

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved